Welcome to LookChem.com Sign In|Join Free
  • or
4-Pyrrolidin-1-yl aniline is a chemical compound characterized by a pyrrolidine ring connected to an aniline group. It serves as a versatile building block in organic synthesis, playing a crucial role in the creation of pharmaceuticals, agrochemicals, and materials science. Known for its capacity to form stable complexes with metal ions, 4-Pyrrolidin-1-yl aniline is a significant component in coordination chemistry. Furthermore, it has been investigated for its potential in developing new materials with tailored electronic and optical properties, making it a valuable asset in chemical research and development due to its distinctive structure and reactivity.

2632-65-7

Post Buying Request

2632-65-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2632-65-7 Usage

Uses

Used in Pharmaceutical Industry:
4-Pyrrolidin-1-yl aniline is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to form stable complexes with metal ions, which can enhance the efficacy and stability of drug molecules.
Used in Agrochemical Industry:
In agrochemicals, 4-Pyrrolidin-1-yl aniline is utilized as a building block for the development of new compounds that can improve crop protection and yield by targeting specific pests or diseases.
Used in Materials Science:
4-Pyrrolidin-1-yl aniline is employed as a component in the creation of advanced materials with unique electronic and optical properties, contributing to the advancement of technologies in areas such as electronics, photonics, and energy storage.
Used in Coordination Chemistry:
As a vital component in coordination chemistry, 4-Pyrrolidin-1-yl aniline is used to form complexes with metal ions, which can be applied in various fields including catalysis, sensing, and the development of new materials with specialized functions.
Used in Chemical Research and Development:
4-Pyrrolidin-1-yl aniline is utilized as a valuable tool in chemical research and development due to its unique structure and reactivity, enabling the exploration of new synthetic pathways and the discovery of novel compounds with potential applications across various industries.

Check Digit Verification of cas no

The CAS Registry Mumber 2632-65-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,6,3 and 2 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 2632-65:
(6*2)+(5*6)+(4*3)+(3*2)+(2*6)+(1*5)=77
77 % 10 = 7
So 2632-65-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H14N2/c11-9-3-5-10(6-4-9)12-7-1-2-8-12/h3-6H,1-2,7-8,11H2

2632-65-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-PYRROLIDIN-1-YLANILINE

1.2 Other means of identification

Product number -
Other names pyrrolidinylaniline

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2632-65-7 SDS

2632-65-7Synthetic route

4-(1-oxy-pyrrolidin-1-yl)-phenylamine

4-(1-oxy-pyrrolidin-1-yl)-phenylamine

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
With copper(l) iodide; N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 35 - 40℃; for 3h;96%
1-(4-nitro-phenyl)-pyrrolidine
10220-22-1

1-(4-nitro-phenyl)-pyrrolidine

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
With hydrogen In methanol; ethyl acetate at 100℃; for 0.333333h; Flow reactor; Green chemistry; chemoselective reaction;93%
With ammonium chloride; zinc In tetrahydrofuran; methanol at 0 - 20℃; for 18h;91.2%
With palladium 10% on activated carbon; hydrogen In ethanol at 20℃; for 9h; Inert atmosphere; Schlenk technique;85%
1-(4-nitrophenyl)piperidine
6574-15-8

1-(4-nitrophenyl)piperidine

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
With palladium 10% on activated carbon; hydrazine hydrate In ethanol for 12h; Reflux;80%
1-(4-bromo-phenyl)-pyrrolidine
22090-26-2

1-(4-bromo-phenyl)-pyrrolidine

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
Stage #1: 1-(4-bromo-phenyl)-pyrrolidine With magnesium In tetrahydrofuran Inert atmosphere;
Stage #2: With C10H17NO In tetrahydrofuran; toluene at -78℃; for 2h; Inert atmosphere;
Stage #3: With ammonium chloride In tetrahydrofuran; water; toluene Inert atmosphere;
57%
pyrrolidine
123-75-1

pyrrolidine

4-bromo-aniline
106-40-1

4-bromo-aniline

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
With cesium hydroxide In dimethyl sulfoxide at 120℃; for 0.166667h;52%
1-(4-nitroso-phenyl)-pyrrolidine; hydrochloride

1-(4-nitroso-phenyl)-pyrrolidine; hydrochloride

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
With hydrogenchloride; tin
1,4-dichlorobutane
110-56-5

1,4-dichlorobutane

1,4-phenylenediamine
106-50-3

1,4-phenylenediamine

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
With 1,2-dichloro-benzene at 110℃;
tetrahydrofuran
109-99-9

tetrahydrofuran

1,4-phenylenediamine
106-50-3

1,4-phenylenediamine

A

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

B

1,4-di(pyrrolidin-1-yl)benzene
50771-64-7

1,4-di(pyrrolidin-1-yl)benzene

Conditions
ConditionsYield
titanium(IV) oxide at 250 - 300℃; Yield given. Yields of byproduct given;
4-chlorobenzonitrile
100-00-5

4-chlorobenzonitrile

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: ethanol
2: nickel-chromium oxide catalyst; methanol / 80 °C / 147102 Torr / Hydrogenation
View Scheme
Multi-step reaction with 2 steps
2: Raney nickel; ethanol / 60 °C / 2206.5 Torr / Hydrogenation
View Scheme
Multi-step reaction with 2 steps
1: potassium carbonate; Aliquat (at)366 / N,N-dimethyl-formamide / 24 h / 100 °C
2: ammonium hydroxide; sodium dithionite / water / 0.25 h / Reflux
View Scheme
C15H22N2O2
1258532-14-7

C15H22N2O2

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
With hydrogenchloride In 1,4-dioxane; dichloromethane at 20℃; for 6h;
para-nitrophenyl bromide
586-78-7

para-nitrophenyl bromide

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: potassium carbonate / N,N-dimethyl-formamide / Reflux
2: hydrogen; palladium 10% on activated carbon / methanol / 20 °C
View Scheme
Multi-step reaction with 2 steps
1: potassium carbonate; tertamethylammonium iodide / dimethyl sulfoxide / 12 h / 80 °C
2: palladium 10% on activated carbon; hydrogen / methanol; ethyl acetate / 3 h / 20 °C
View Scheme
4-Fluoronitrobenzene
350-46-9

4-Fluoronitrobenzene

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: potassium carbonate / dimethyl sulfoxide / 20 °C / Inert atmosphere; Schlenk technique
2: hydrogen; palladium 10% on activated carbon / ethanol / 9 h / 20 °C / Inert atmosphere; Schlenk technique
View Scheme
Multi-step reaction with 2 steps
1: potassium carbonate / N,N-dimethyl-formamide / 5 h / 110 °C / Inert atmosphere
2: palladium 10% on activated carbon; hydrazine hydrate / ethanol / 12 h / Reflux
View Scheme
Multi-step reaction with 2 steps
1: potassium carbonate / N,N-dimethyl-formamide / 40 °C
2: 5%-palladium/activated carbon; hydrogen / ethanol; water / 20 °C
View Scheme
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

9-(cyclopentyl)-2,6-(dichloro)-9H-purine
211733-67-4

9-(cyclopentyl)-2,6-(dichloro)-9H-purine

(2-chloro-9-cyclopentyl-9H-purin-6-yl)-(4-pyrrolidin-1-yl-phenyl)amine

(2-chloro-9-cyclopentyl-9H-purin-6-yl)-(4-pyrrolidin-1-yl-phenyl)amine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In propan-1-ol at 100℃; Inert atmosphere; Sealed tube;92%
With N-ethyl-N,N-diisopropylamine In propan-1-ol at 100℃; Sealed tube; Inert atmosphere;92%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Glyoxal
131543-46-9

Glyoxal

N,N'-(1,2-ethanediylidene)bis(4-pyrrolidin-1-ylbenzeneamine)
1172626-91-3

N,N'-(1,2-ethanediylidene)bis(4-pyrrolidin-1-ylbenzeneamine)

Conditions
ConditionsYield
In propan-1-ol; water at 70℃; for 24h; Inert atmosphere;91%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

C14H14ClN5O2

C14H14ClN5O2

3-(3,5-dimethoxyphenethyl)-N-(4-(pyrrolidin-1-yl)phenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine

3-(3,5-dimethoxyphenethyl)-N-(4-(pyrrolidin-1-yl)phenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine

Conditions
ConditionsYield
In butan-1-ol at 100℃; Inert atmosphere; Schlenk technique;90%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Cbz-Ile-4-pyrrolidynylanilide

Cbz-Ile-4-pyrrolidynylanilide

Conditions
ConditionsYield
Stage #1: N-benzyloxycarbonyl isoleucine With 1-methyl-1H-imidazole In dichloromethane at 0 - 5℃; for 0.166667h;
Stage #2: With methanesulfonyl chloride In dichloromethane at -5℃; for 0.333333h;
Stage #3: 4-pyrrolidin-1-yl-aniline In dichloromethane at 20℃; for 2h;
89%
succinic acid anhydride
108-30-5

succinic acid anhydride

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

4-(4-(pyrrolidin-1-yl)phenylamino)-4-oxobutanoic acid

4-(4-(pyrrolidin-1-yl)phenylamino)-4-oxobutanoic acid

Conditions
ConditionsYield
In dichloromethane at 20℃; for 24h; Cooling;87%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

25,26,27,28-tetraproxycalix[4]arene-5,17-dicarboxoyl chloride
191880-48-5

25,26,27,28-tetraproxycalix[4]arene-5,17-dicarboxoyl chloride

5,17-bis(N-(4-(pyrrolidin-1-yl)phenyl)aminocarbonyl)-25,26,27,28-tetrapropoxycalix<4>arene

5,17-bis(N-(4-(pyrrolidin-1-yl)phenyl)aminocarbonyl)-25,26,27,28-tetrapropoxycalix<4>arene

Conditions
ConditionsYield
With triethylamine In dichloromethane at 25℃; for 1h;85%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

5-fluoro-2-hydroxybenzaldehyde
347-54-6

5-fluoro-2-hydroxybenzaldehyde

4-(1-pyrrolidinyl)-benzenamine salicylaldehyde

4-(1-pyrrolidinyl)-benzenamine salicylaldehyde

Conditions
ConditionsYield
In ethanol for 8h; Reflux;83.7%
Z-Leu-OH
2018-66-8

Z-Leu-OH

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

Cbz-Leu-4-pyrrolidynylanilide
1286716-55-9

Cbz-Leu-4-pyrrolidynylanilide

Conditions
ConditionsYield
Stage #1: Z-Leu-OH With 1-methyl-1H-imidazole In dichloromethane at 0 - 5℃; for 0.166667h;
Stage #2: With methanesulfonyl chloride In dichloromethane at -5℃; for 0.333333h;
Stage #3: 4-pyrrolidin-1-yl-aniline In dichloromethane at 20℃; for 2h;
83%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

4-Fluoronitrobenzene
350-46-9

4-Fluoronitrobenzene

N,N-bis(4-nitrophenyl)-4-(pyrrolidin-1-yl)aniline

N,N-bis(4-nitrophenyl)-4-(pyrrolidin-1-yl)aniline

Conditions
ConditionsYield
With cesium fluoride In dimethyl sulfoxide at 120℃; for 24h; Inert atmosphere;75%
2-tert-butyl-4-chloro-5-phenylisothiazol-3(2H)-one 1,1-dioxide
898270-94-5

2-tert-butyl-4-chloro-5-phenylisothiazol-3(2H)-one 1,1-dioxide

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

2-tert-butyl-5-phenyl-4-[(4-pyrrolidin-1-ylphenyl)amino]isothiazol-3(2H)-one 1,1-dioxide

2-tert-butyl-5-phenyl-4-[(4-pyrrolidin-1-ylphenyl)amino]isothiazol-3(2H)-one 1,1-dioxide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide; acetonitrile at 120℃; for 1h; Microwave irradiation;69%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

7-chloro-5-cyclopentyl-[1,2,4]triazolo[4,3-f]pteridin-4(5H)-one

7-chloro-5-cyclopentyl-[1,2,4]triazolo[4,3-f]pteridin-4(5H)-one

5-cyclopentyl-7-((4-(pyrrolidin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-f]pteridin-4(5H)-one

5-cyclopentyl-7-((4-(pyrrolidin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-f]pteridin-4(5H)-one

Conditions
ConditionsYield
With toluene-4-sulfonic acid In butan-1-ol at 100℃; for 15h;66.1%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

2,5-dichloro-4-(3-nitrophenoxy)pyrimidine
76661-24-0

2,5-dichloro-4-(3-nitrophenoxy)pyrimidine

5-chloro-4-(3-nitrophenoxy)-N-(4-(pyrrolidin-1-yl)phenyl)pyrimidin-2-amine

5-chloro-4-(3-nitrophenoxy)-N-(4-(pyrrolidin-1-yl)phenyl)pyrimidin-2-amine

Conditions
ConditionsYield
With trifluoroacetic acid In iso-butanol at 100℃;65.7%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

7-chloro-5-cyclopentyl-tetrazolo[4,3-f]pteridin-4(5H)-one

7-chloro-5-cyclopentyl-tetrazolo[4,3-f]pteridin-4(5H)-one

5-cyclopentyl-7-((4-(pyrrolidin-1-yl)phenyl)amino)tetrazolo[1,5-f]pteridin-4(5H)-one

5-cyclopentyl-7-((4-(pyrrolidin-1-yl)phenyl)amino)tetrazolo[1,5-f]pteridin-4(5H)-one

Conditions
ConditionsYield
With toluene-4-sulfonic acid In butan-1-ol at 100℃; for 15h;65.2%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

2-iodo-4-(pyrrolidin-1-yl)aniline

2-iodo-4-(pyrrolidin-1-yl)aniline

Conditions
ConditionsYield
With hydrogenchloride; potassium iodate; potassium iodide In methanol; water63%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

7-chloro-5-cyclopentyl-1-methyl-[1,2,4]triazolo[4,3-f]pteridin-4(5H)-one

7-chloro-5-cyclopentyl-1-methyl-[1,2,4]triazolo[4,3-f]pteridin-4(5H)-one

5-cyclopentyl-1-methyl-7-((4-(pyrrolidin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-f]pteridin-4(5H)-one

5-cyclopentyl-1-methyl-7-((4-(pyrrolidin-1-yl)phenyl)amino)-[1,2,4]triazolo[4,3-f]pteridin-4(5H)-one

Conditions
ConditionsYield
With toluene-4-sulfonic acid In butan-1-ol at 100℃; for 15h;55.7%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302964-08-5

2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide

N-(2-chloro-6-methylphenyl)-2-((2-methyl-6-((4-(pyrrolidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)thiazole-5-carboxamide
1587622-99-8

N-(2-chloro-6-methylphenyl)-2-((2-methyl-6-((4-(pyrrolidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)thiazole-5-carboxamide

Conditions
ConditionsYield
With hydrogenchloride In 1,4-dioxane at 110℃; for 12h;49%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

(4-((6,7-dimethoxyquinazolin-4-yl)oxy)-2,6-difluorophenyl)-2-oxoacetic acid

(4-((6,7-dimethoxyquinazolin-4-yl)oxy)-2,6-difluorophenyl)-2-oxoacetic acid

2-(4-((6,7-dimethoxyquinazolin-4-yl)oxy)-2,6-difluorophenyl)-N-(4-(pyrrolidin-1-yl)phenyl)-2-oxoacetamide

2-(4-((6,7-dimethoxyquinazolin-4-yl)oxy)-2,6-difluorophenyl)-N-(4-(pyrrolidin-1-yl)phenyl)-2-oxoacetamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; HATU In acetonitrile at 20℃; for 12h;47%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

C15H11Cl2FN6

C15H11Cl2FN6

4-(3-(3-chloro-4-fluorophenyl)-5,6-dihydro-[1,2,4]triazolo-[4,3-a]pyrazin-7(8H)-yl)-N-(4-(pyrrolidin-1-yl)phenyl)pyrimidin-2-amine

4-(3-(3-chloro-4-fluorophenyl)-5,6-dihydro-[1,2,4]triazolo-[4,3-a]pyrazin-7(8H)-yl)-N-(4-(pyrrolidin-1-yl)phenyl)pyrimidin-2-amine

Conditions
ConditionsYield
With toluene-4-sulfonic acid In isopropyl alcohol at 90℃; for 24h;30%
(S)-4-methyl-2-(toluene-4-sulfonamido)pentanoic acid
1220-80-0, 67368-40-5, 150614-61-2

(S)-4-methyl-2-(toluene-4-sulfonamido)pentanoic acid

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

(S)-4-methyl-2-(4-methylphenylsulfonamido)-N-(4-(pyrrolidin-1-yl)phenyl)pentanamide

(S)-4-methyl-2-(4-methylphenylsulfonamido)-N-(4-(pyrrolidin-1-yl)phenyl)pentanamide

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 18h; Inert atmosphere;24%
indole
120-72-9

indole

4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

oxalyl dichloride
79-37-8

oxalyl dichloride

2-(1H-indol-3-yl)-2-oxo-N-(4-(pyrrolidin-1-yl)phenyl)acetamide
1257651-78-7

2-(1H-indol-3-yl)-2-oxo-N-(4-(pyrrolidin-1-yl)phenyl)acetamide

Conditions
ConditionsYield
Stage #1: indole; oxalyl dichloride In tetrahydrofuran at 20℃; for 1h; Inert atmosphere;
Stage #2: 4-pyrrolidin-1-yl-aniline With 2,6-dimethylpyridine; dmap In tetrahydrofuran at 45℃; for 18h; Inert atmosphere;
16%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

3-(2,6-dichlorophenyl)-7-methylsulfanyl-2H-pyrimido[5,4-e][1,3]oxazin-4-one

3-(2,6-dichlorophenyl)-7-methylsulfanyl-2H-pyrimido[5,4-e][1,3]oxazin-4-one

3-(2,6-dichlorophenyl)-7-((4-(pyrrolidin-1-yl)phenyl)amino)-2,3-dihydro-4H-pyrimido[5,4-e][1,3]oxazin-4-one

3-(2,6-dichlorophenyl)-7-((4-(pyrrolidin-1-yl)phenyl)amino)-2,3-dihydro-4H-pyrimido[5,4-e][1,3]oxazin-4-one

Conditions
ConditionsYield
Stage #1: 3-(2,6-dichlorophenyl)-7-methylsulfanyl-2H-pyrimido[5,4-e][1,3]oxazin-4-one With 3-chloro-benzenecarboperoxoic acid In toluene at 20℃; for 0.5h;
Stage #2: 4-pyrrolidin-1-yl-aniline With N-ethyl-N,N-diisopropylamine In toluene at 20℃; for 12h;
14.66%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

3-fluoro-5-formyl-4-hydroxybenzoic acid

3-fluoro-5-formyl-4-hydroxybenzoic acid

1-(3-fluoro-5-formyl-4-hydroxyphenyl)-3-(4-(pyrrolidin-1-yl)phenyl)urea

1-(3-fluoro-5-formyl-4-hydroxyphenyl)-3-(4-(pyrrolidin-1-yl)phenyl)urea

Conditions
ConditionsYield
Stage #1: 4-pyrrolidin-1-yl-aniline; 3-fluoro-5-formyl-4-hydroxybenzoic acid In 1,4-dioxane at 20℃; for 0.166667h;
Stage #2: With diphenyl phosphoryl azide; triethylamine In 1,4-dioxane at 20 - 90℃; for 3.5h;
Stage #3: With hydrogenchloride In water at 20℃; for 1h;
7%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

3-fluoro-5-formyl-4-hydroxybenzene-1-sulfonyl chloride

3-fluoro-5-formyl-4-hydroxybenzene-1-sulfonyl chloride

3-fluoro-5-formyl-4-hydroxy-N-(4-(pyrrolidin-1-yl)phenyl)benzenesulfonamide

3-fluoro-5-formyl-4-hydroxy-N-(4-(pyrrolidin-1-yl)phenyl)benzenesulfonamide

Conditions
ConditionsYield
Stage #1: 4-pyrrolidin-1-yl-aniline; 3-fluoro-5-formyl-4-hydroxybenzene-1-sulfonyl chloride With 4-methyl-morpholine In dichloromethane for 5h;
Stage #2: With hydrogenchloride In dichloromethane for 3h;
4%
4-pyrrolidin-1-yl-aniline
2632-65-7

4-pyrrolidin-1-yl-aniline

4-iodobutyronitrile
6727-73-7

4-iodobutyronitrile

N,N-bis-(3-cyano-propyl)-4-pyrrolidino-aniline
855624-33-8

N,N-bis-(3-cyano-propyl)-4-pyrrolidino-aniline

Conditions
ConditionsYield
With water; potassium carbonate; sodium hydrogensulfite

2632-65-7Relevant academic research and scientific papers

Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer

Yang, Huali,Wang, Xiaobing,Wang, Cheng,Yin, Fucheng,Qu, Lailiang,Shi, Cunjian,Zhao, Jinhua,Li, Shang,Ji, Limei,Peng, Wan,Luo, Heng,Cheng, Maosheng,Kong, Lingyi

, (2020/12/15)

NUAK, the member of AMPK (AMP-activated protein kinase) family of protein kinases, is phosphorylated and activated by the LKB1 (liver kinase B1) tumor suppressor protein kinase. Recent work has indicated that NUAK1 is a key component of the antioxidant stress response pathway, and the inhibition of NUAK1 will suppress the growth and survival of colorectal tumors. As a promising target for anticancer drugs, few inhibitors of NUAK were developed. With this goal in mind, based on NUAK inhibitor WZ4003, a series of derivatives has been synthesized and evaluated for anticancer activity. Compound 9q, a derivative of WZ4003 by removing a methoxy group, was found to be the most potential one with stronger inhibitory against NUAK1/2 enzyme activity, tumor cell proliferation and inducing apoptosis of tumor cells. By in vivo efficacy evaluations of colorectal SW480 xenografts, 9q suppresses tumor growth more effectively with an excellent safety profile in vivo and is therefore seen as a suitable candidate for further investigation.

Synthesis and Structure-Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy

Sivaraman, Aneesh,Kim, Dae Gyu,Bhattarai, Deepak,Kim, Minkyoung,Lee, Hwa Young,Lim, Semi,Kong, Jiwon,Goo, Ja-Il,Shim, Seunghwan,Lee, Seungbeom,Suh, Young-Ger,Choi, Yongseok,Kim, Sunghoon,Lee, Kyeong

, p. 5139 - 5158 (2020/05/05)

AIMP2-DX2, a splicing variant of AIMP2, is up-regulated in lung cancer, possesses oncogenic activity, and results in tumorigenesis. Specifically inhibiting the interaction between AIMP2-DX2 and HSP70 to suppress AIMP2-DX2-dependent cancers with small molecules is considered a promising avenue for cancer therapeutics. Optimization of hit BC-DXI-04 (IC50 = 40.1 μM) provided new potent sulfonamide based AIMP2-DX2 inhibitors. Among these, BC-DXI-843 showed improved inhibition against AIMP2-DX2 (IC50 = 0.92 μM) with more than 100-fold selectivity over AIMP2 in a luciferase assay. Several binding assays indicated that this compound effectively induces cancer cell apoptosis by specifically interrupting the interaction between DX2 and HSP70, which leads to the degradation of DX2 via Siah1-mediated ubiquitination. More importantly, BC-DXI-843 demonstrated in vivo efficacy in a tumor xenograft mouse model (H460 cells) at a dosage of 50 mg/kg, suggesting it as a promising lead for development of novel therapeutics targeting AIMP2-DX2 in lung cancer.

Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents

Zhang, Li,Wu, Yuhang,Yang, Guixiang,Gan, Haixian,Sang, Dayong,Zhou, Jiye,Su, Lin,Wang, Rui,Ma, Lei

supporting information, (2020/11/03)

A total of 26 compounds based on osthole skeleton were designed, synthesized. Their cytoprotective abilities of antioxidation, anti-inflammation and Aβ42(Amyloid β-protein 42)-induced neurotoxicity were evaluated by MTT assays. Mechanism of the action of selected compounds were investigated by molecular docking. AlogP, logS and blood–brain barrier (BBB) permeability of all these compounds were simulated by admetSAR. Most of the compounds showed better antioxidative and anti-inflammatory activities compared with osthole, especially OST7 and OST17. The compound OST7 showed relative high activity in neuroprotection against H2O2 (45.7 ± 5.5%), oxygen glucose deprivation (64.6 ± 4.8%) and Aβ42 (61.4 ± 5.2%) at a low concentration of 10 μM. EC50 of selected compounds were measured in both H2O2 and OGD induced cytotoxicity models. Moreover, NO inhibiting ability of OST17(50.4 ± 7.1%) already surpassed the positive drug indomethacin. The structure activity relationship study indicated that introduction of piperazine group, tetrahydropyrrole group and aromatic amine group might be beneficial for enhancement of osthole neuroprotective properties. Molecular docking explained that the reason OST7 exhibited relatively stronger neuroprotection against Aβ because of the greater area of interactions between molecule and target protein. OST7 and OST17 both provided novel methods to investigate osthole as anti-AD drugs.

Design, synthesis and biological evaluation of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivative as potent antitumor agents

Hou, Yunlei,Zhu, Liangyu,Li, Zhiwei,Shen, Qi,Xu, Qiaoling,Li, Wei,Liu, Yajing,Gong, Ping

, p. 690 - 709 (2019/01/04)

To develop novel therapeutic agents with anticancer activities, two series of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivatives were designed and synthesized. All compounds were tested for anti-proliferative activities against five cancer cell lines. The structure-activity relationships (SARs) studies were conducted through the variation in two regions, the moiety of A ring and the terminal aniline B on pteridinone core. 1-Methyl-1,2,4-triazole derivative L7 with 2,6-dimethylpiperazine showed the most potent antiproliferative activity against A549, PC-3, HCT116, MCF-7 and MDA-MB-231 cell lines with IC50 values of 0.16 μM, 0.30 μM, 0.51 μM, 0.30 μM, and 0.70 μM, respectively. Combined with the results of the molecular docking and enzymatic studies, the PLK1 was very likely to be one of the drug targets of compound L7. Furthermore, to clarify the anticancer mechanism of compound L7, further explorations in the bioactivity were conducted. The results showed that compound L7 obviously inhibited proliferation of A549 cell lines, induced a great decrease in mitochondrial membrane potential leading to apoptosis of cancer cells, suppressed the migration of tumor cells, and arrested G1 phase of A549 cells.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

-

, (2019/04/25)

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

Design, synthesis and biological evaluation of novel 2,4-diaminopyrimidine derivatives as potent antitumor agents

Hu, Gang,Wang, Chu,Xin, Xin,Li, Shuaikang,Li, Zefei,Zhao, Yanfang,Gong, Ping

, p. 10190 - 10202 (2019/07/03)

For developing novel therapeutic agents with anticancer activities, two series of novel 2,4-diaminopyrimidine derivatives possessing triazolopiperazine or 1,4,8-triazaspiro[4.5]decan-3-one scaffolds were designed and synthesized. Preliminary investigations showed that some compounds exhibited moderate to excellent potency against four tested cancer cell lines as compared with palbociclib and momelotinib. In particular, the most promising compounds 9k and 13f showed the most potent antitumor activities with IC50 values of 2.14/1.98 μM, 3.59/2.78 μM, 5.52/4.27 μM, and 3.69/4.01 μM against A549, HCT-116, PC-3 and MCF-7 cell lines, respectively. Structure-activity relationship (SAR) studies were conducted based on the variation of the moiety of the aromatic ring and the terminal aniline on the pyrimidine core. Furthermore, the mechanism of their anticancer activity was clarified by further exploring the bioactivity. The results showed that compound 9k obviously inhibited the proliferation of A549 cell lines, induced a great decrease in the mitochondrial membrane potential leading to apoptosis of cancer cells, suppressed the migration of tumor cells and prolonged the A549 cell cycle distribution, representing blockage at the G2-M phase and accumulation at the S phase.

Hydrogenation of nitroarenes to anilines in a flow reactor using polystyrene supported rhodium in a catalyst-cartridge (Cart-Rh@PS)

Sharma, Saurabh,Yamini,Das, Pralay

supporting information, p. 1764 - 1769 (2019/01/28)

The present methodology described the chemo-selective hydrogenation of various nitroarenes in a flow reactor under polystyrene supported rhodium in a catalyst-cartridge (Cart-Rh@PS) as a heterogeneous nano-catalyst. The polystyrene supported Rh (Rh@PS) nanoparticles (NPs) were prepared by following our earlier reported protocol and packed inside the catalyst-cartridge (Cat-Cart) to obtain Cart-Rh@PS, which is compatible with ThalesNano's H-Cube Pro flow system. The advantages of the prepacked catalyst Cart-Rh@PS are as follows: no need for catalyst activation up to 12 runs, negligible metal leaching detected by ICP-AES analysis and significantly less back pressure generated under the flow conditions. The same catalyst, Cart-Rh@PS, was also effective up to a 1 gram scale for the reduction of nitroarenes and reusable for successive runs. The hydrogenation in the flow reactor is a greener approach for the reduction of nitroarenes to their corresponding anilines in high yields.

AMINATION AND HYDROXYLATION OF ARYLMETAL COMPOUNDS

-

Paragraph 0098; 0134; 0135; 0190, (2018/03/25)

In one aspect, the present disclosure provides methods of preparing a primary or secondary amine and hydroxylated aromatic compounds. In some embodiments, the aromatic compound may be unsubstituted, substituted, or contain one or more heteroatoms within the rings of the aromatic compound. The methods described herein may be carried out without the need for transition metal catalysts or harsh reaction conditions.

Supported Rhodium Nanoparticles Catalyzed Reduction of Nitroarenes, Arylcarbonyls and Aryl/Benzyl Sulfoxides using Ethanol/Methanol as In Situ Hydrogen Source

Sharma, Saurabh,Bhattacherjee, Dhananjay,Das, Pralay

supporting information, p. 2131 - 2137 (2018/04/17)

A facile reduction reaction of nitroarenes, aryl carbonyls and aryl/benzyl sulfoxides was performed under polystyrene supported rhodium (Rh@PS) catalyzed conditions using ethanol/methanol as in situ hydrogen source. The catalyst Rh@PS played a pivotal role in the oxidation of ethanol/methanol in the presence of traces of aerial oxygen and base to produce hydrogen gas, enough for further reduction reaction. Transmission electron microscopy (TEM) analysis indicated that the average particle size of the Rh nanoparticles (NPs) lies between 2–3 nm; this is responsible for its high catalytic activity. The advantages of Rh@PS are its catalytic activity, easy preparation, recovery, recyclability for several runs, and low metal leaching during reaction. (Figure presented.).

Dramatic Acceleration of an Acyl Transfer-Initiated Cascade by Using Electron-Rich Amidine-Based Catalysts

Ahlemeyer, Nicholas A.,Streff, Emma V.,Muthupandi, Pandi,Birman, Vladimir B.

supporting information, p. 6486 - 6489 (2017/12/26)

A tandem rearrangement of α,β-unsaturated thioesters into tricyclic ene-lactones fails with conventional amidine-based catalysts, but becomes possible when their electron-rich analogs are employed. A highly diastereo- and enantioselective version of this process has been developed using H-PIP 1b, a chiral catalyst prepared over a decade ago, but never utilized since its disclosure.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 2632-65-7